Stockscreener 앱 받기
18.35
2.97%
0.53
시간 외 거래:
18.20
-0.15
-0.82%
전일 마감가:
$17.82
열려 있는:
$17.71
하루 거래량:
328.88K
Relative Volume:
0.94
시가총액:
$496.23M
수익:
$157.75M
순이익/손실:
$-29.73M
주가수익비율:
6.1371
EPS:
2.99
순현금흐름:
$-21.00M
1주 성능:
-4.03%
1개월 성능:
-23.16%
6개월 성능:
-32.71%
1년 성능:
-6.28%
1일 변동 폭
$17.26
$18.40
1주일 범위
$17.26
$19.01
52주 변동 폭
$17.26
$45.00
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect - Yahoo Finance
Empire Life Investments Inc. Makes New $3.50 Million Investment in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (ARCT) Scheduled to Post Earnings on Thursday - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024 - Business Wire
Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Arcturus falls after detailed Phase 1 data for cystic fibrosis therapy - MSN
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 6.1%What's Next? - MarketBeat
Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain - Yahoo Finance
8,235 Shares in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Acquired by SG Americas Securities LLC - Defense World
A slow start for self-amplifying mRNA vaccines - Yahoo Finance
Vontobel Holding Ltd. Trims Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 5.8% Following Insider Selling - MarketBeat
AQR Capital Management LLC Has $285,000 Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Insider Sale at Arcturus Therapeutics Holdings Inc (ARCT) - GuruFocus.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula Sells 12,000 Shares - MarketBeat
Arcturus Therapeutics executive sells $249,121 in stock By Investing.com - Investing.com Canada
Arcturus Therapeutics executive sells $249,121 in stock - Investing.com India
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Update - MarketBeat
mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way - GlobeNewswire Inc.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Price Target from Analysts - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Consensus Price Target from Analysts - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 5.9%Time to Sell? - MarketBeat
Squarepoint Ops LLC Takes Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Marshall Wace LLP Cuts Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.4% – Here’s Why - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.4%Time to Sell? - MarketBeat
Point72 Asia Singapore Pte. Ltd. Makes New Investment in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
ARCTURUS THERAPEUTICS HOLDINGS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com
Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified - Simply Wall St
Dimensional Fund Advisors LP Sells 185,598 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Leerink Partners’s latest rating for ARCT stock - Knox Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Unveiling 3 Analyst Insights On Arcturus Therapeutics - Benzinga
Arcturus Therapeutics' (ARCT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses - Yahoo Finance
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination - Lelezard
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination – Company AnnouncementFT.com - Financial Times
Here's Why Investors Should Invest in Arcturus Stock Now - MSN
American Century Companies Inc. Has $2.49 Million Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Wall Street SWOT: Arcturus Therapeutics stock rides wave of vaccine innovation - Investing.com
Deerfield Management Company L.P. Series C Takes $958,000 Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
mRNA Vaccine and Therapeutics Market Global Report to 2035, with Profiles of Arcturus Therapeutics, BioNTech, CureVac, Ethris, Immorna, Moderna, Providence Therapeutics and Suzhou Abogen Biosciences - Yahoo Finance
XTX Topco Ltd Invests $596,000 in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Trading 4.3% Higher - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 3.5% - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.5% - Defense World
Cystic Fibrosis (CF) Therapeutics Market Report 2024: Global Size, Share, Growth, Trends, Forecast To 2033 - WhaTech
Quest Partners LLC Raises Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Trading Up 6.6% - MarketBeat
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):